A High Level of Soluble CD40L Is Associated with *P. aeruginosa* Infection in Patients with Cystic Fibrosis

Adriana Ester Bustamante¹ *, José Carlos Jaime-Pérez², Paula Cordero-Pérez³, Gabriela Galindo-Rodríguez⁴, Linda Elsa Muñoz-Espinosa³, César Daniel Villarreal-Villarreal², Roberto Mercado-Longoria¹

¹ Clínica de Fibrosis Quística, Servicio de Neumología, Universidad Autónoma de Nuevo León, Facultad de Medicina, Hospital Universitario “Dr. José E. González”, Monterrey Nuevo León, México, ² Departamento de Hematología, Universidad Autónoma de Nuevo León, Facultad de Medicina, Hospital Universitario “Dr. José E. González”, Monterrey Nuevo León, México, ³ Unidad de Hígado, Universidad Autónoma de Nuevo León, Facultad de Medicina, Hospital Universitario “Dr. José E. González”, Monterrey Nuevo León, México, ⁴ Servicio de Alergia e Inmunología, Universidad Autónoma de Nuevo León, Facultad de Medicina, Hospital Universitario “Dr. José E. González”, Monterrey Nuevo León, México

* abustamante@ceprep.edu.mx

Abstract

Objective

The aim of this study was to evaluate whether the concentration of sCD40L, a product of platelet activation, correlates with the presence of *Pseudomonas aeruginosa* in the airway of patients with cystic fibrosis (CF) and to determine its possible clinical association.

Methods

Sixty patients with CF, ranging in age from 2 months to 36 years, were studied. The demographic, cystic fibrosis transmembrane conductance regulator (CFTR) genotype, spirometry measurements, radiographic and tomographic scans, platelet count in peripheral blood, sCD40L, IL-6, TNF-α and ICAM1 data were collected. Infection-colonization of the airway was evaluated using sputum and throat swab cultures; the levels of anti-*Pseudomonas aeruginosa* antibodies (Anti-PaAb) were evaluated.

Results

Patients with CF and chronic colonization had anti-PaAb values of 11.6 ± 2.1 ELISA units (EU) and sCD40L in plasma of 1530.9 ± 1162.3 pg/mL; those with intermittent infection had 5.7 ± 2.7 EU and 2243.6 ± 1475.9 pg/mL; and those who were never infected had 3.46 ± 1.8 EU (p<0.001) and 1008.1 ± 746.8 pg/mL (p≤0.01), respectively. The cutoff value of sCD40L of 1255 pg/mL was associated with an area under the ROC (receiver operating characteristic curve) of 0.84 (95% CI, 0.71 to 0.97), reflecting *P. aeruginosa* infection with a sensitivity of 73% and a specificity of 89%. Lung damage was determined using the Brasfield Score, the Bhalla Score, and spirometry (FVC%, FEV1%) and found to be significantly different among the groups (p≤0.001).
Conclusion
Circulating sCD40L levels are increased in patients with cystic fibrosis and *P. aeruginosa* infection. Soluble CD40L appears to reflect infection and provides a tool for monitoring the evolution of lung deterioration.

Introduction
Cystic fibrosis (CF) is one of the most common inherited diseases resulting in a shortened life span. It affects approximately 70,000 people worldwide [1–2]. CF is an autosomal recessive disease that is caused by mutations in the gene encoding the CF transmembrane conductance regulator (CFTR), located on the long arm of the chromosome 7[3]. There are more than 2000 CFTR mutations. At the airway level, these mutations lead to defects in the CFTR causing reduced chloride secretion, which favors the reabsorption of sodium and results in dried secretions, poor mucociliary clearance, and airway obstruction [3–4].

Lung disease in CF, characterized by chronic endobronchial infection with specific pathogens, is associated with inflammation dominated by neutrophils that contribute to progressive lung damage [5–7]. Numerous studies have shown that both infection and inflammation begin early in life [8–9], and they represent a determining factor for the deteriorating lung function and shortened survival. *P. aeruginosa* is the main pathogen that infects patients with CF [10–11].

Controversy exists regarding whether lung inflammation is present in the CF lung even without infection or whether inflammation is an exaggerated response to sustained bacterial infections. Undoubtedly, lung inflammation is more intense in the presence of chronic infection [5–6, 8]. Regardless of whether inflammation precedes or follows infection in patients with CF, the inflammation is severe. Research has indicated that platelets contribute significantly to the incidence of inflammation [12].

Platelets secrete co-stimulatory molecules such as CD40L. The soluble form of CD40L (sCD40L) in human circulation is nearly entirely derived from platelets [13]. This study evaluated the presence of anti-*P. aeruginosa* antibodies (anti-PaAb) and the concentration of sCD40L and their relationship with *P. aeruginosa* infection in a cohort of patients with cystic fibrosis.

Materials and Methods
Study design and population
The participants were recruited from the CF clinic of the “Dr. José Eleuterio González” School of Medicine and University Hospital of the Autonomous University of Nuevo Leon in Monterrey, Mexico, from November 2011 to May 2013. The Ethics and Research Committees of the University Hospital José Eleuterio González (Registration no. NM11015) approved this study protocol. Written informed consent was obtained from either the subjects or their caregivers.

We included all patients with a positive diagnosis of CF using electrolytes in sweat, which was performed with pilocarpine iontophoresis (chloride in sweat ≥ 60 mmol/L) and adhered to the procedures from a genetic study using two mutations in CFTR known to cause cystic fibrosis; patients with advanced liver disease or use of systemic corticosteroids were excluded.

This ambispective observational study aimed to assess patients with cystic fibrosis and implement interventions according to standard international guidelines. For our protocol, the
patients were divided according to Leeds criteria into the following groups [14]: 1) patients with chronic *P. aeruginosa* colonization; 2) patients with intermittent infection by the same bacteria; and 3) patients in whom *P. aeruginosa* was never identified.

**Review of clinical records**

We created a database that included demographic parameters; age; sex; age at the time of diagnosis; clinical, biochemical, functional and imaging test results; identified mutations; a history of colonization with *P. aeruginosa* (during the previous year); cultures of sputum and throat swabs; radiographic score; tomographic score; and pulmonary function tests.

**Follow-up of patients with CF**

The follow-up protocol in the CF clinic included monitoring visits at least four times throughout the year, during which nutritional status was assessed by weight and height: weight/height ratio in children under 2 years and/or body mass index (IMC) in individuals over 2 years; also, respiratory clinical symptoms and oxygen saturation by pulse oximetry were assessed, and once a year, blood chemistry and chest X-ray were performed. The chest radiograph was evaluated using the classic radiographic CF score, the Brasfield Radiological Scoring System [15]. From 3 years of age and afterwards, every three years, high-resolution chest tomography was performed and evaluated using the Bhalla score [16].

A respiratory sample was obtained at the initial visit and repeated every three months. Additional samples were obtained if the patient had respiratory symptoms or at the end of eradication treatment. The samples were obtained by spontaneous expectoration or by deep throat swab.

Sputum samples were plated on chocolate agar, EMB agar, sodium azide agar, staphylococcus S110 agar and blood agar. Throat swabs were plated on sheep blood agar. The blood agar and chocolate agar plates were incubated in micro-aerobiosis, and the remainder were incubated aerobically for up to 72 h at 36˚C. Bacterial colonies were identified using conventional biochemical tests and the biochemical system API20 NE (BioMerieux, Inc., Durham, NC, USA).

Pulmonary function tests were performed by spirometry following the guidelines of the American Thoracic Society [17]. The tests were conducted using the Platinum EliteSeries™, BreezeSuite™ version 7.2 SP3 plethysmograph (MGC Diagnostics, St. Paul, MN, USA). The results were expressed as the percentage of the predicted values for FEV1 and FVC by sex, age and height.

The patients were treated with the usual indications, including a hypercaloric diet, pancreatic enzymes, fat-soluble vitamins, nebulized bronchodilator, and Pulmozyme NR, secretion clearance therapy, systemic antibiotics, if needed. Treatment was aimed at eradicating *P. aeruginosa* in the case of infection, initial or recent, with tobramycin 300 mg twice daily inhaled for 28 days.

For the purposes of this protocol, if the patient was stable, a 7.0-mL sample of peripheral blood was obtained, centrifuged and separated into three aliquots of 1.0 mL of serum and frozen at -70˚C to determine the concentration of cytokines (IL-6, ICAM-1, TNF-α, VEGF), sCD40L, and anti-PaAb. A second sample for sCD40L was obtained at the end of the inhaled antibiotic cycle in non-chronic patients in whom positive cultures for *P. aeruginosa* were documented within six months of obtaining the baseline sample and in those who received eradication treatment with inhaled tobramycin.
Analysis of serum parameters

In all patients, a platelet count, the sCD40L fraction, and inflammatory mediators were determined; IL6, ICAM-1, TNF-α, and VEGF were measured using ELISA according to the manufacturer’s instructions (Pre-ProTech, México; ASYS Hitech GmbH Expert ELISA Plus UV G020151, Eugendorf, Austria); and specific antibodies against *Pseudomonas aeruginosa* were measured using the Pseudomonas-CF-IgG ELISA kit (Statens Serum Institut SSI Diagnostica, Hillerød, Denmark).

Statistical analysis

Parametric or non-parametric tests were conducted as appropriate (ANOVA and a homogeneity of numerical variances test). For categorical variables, contingency tables and the chi-squared test were used.

For sCD40L, a ROC (receiver operating curve) analysis, including the area under the curve (AUC), was performed to assess cutoff values for this marker to reflect *P. aeruginosa* infection. For sCD40L measurements before and after eradication therapy, a paired t test for related samples was performed. All values are reported as the means ± SD with 95% confidence intervals. A *P*<0.05 was considered to be statistically significant. The data were collected in a database and were analyzed using SPSS 20.0 for Windows.

Results

During the study period, 64 patients were invited to participate, and 60 met the inclusion criteria and signed the informed consent/assent form. Thirty-one women and 29 men with a mean age of 9.5 ± 7.2 years, who regularly attended the CF clinic, were included in the study. The genetic study was conducted in 49/60 (81.7%) patients and at least one mutation in the CFTR was identified, being homozygous for the F508del in 16/60 (26.7%), heterozygous for the F508del mutation in 21/60 (35%), and two different F508del mutations in 12/60 (20%); in the remaining 11 (18.3%) patients, a molecular study was not performed.

According to the Leeds classification [14], 24 (37.5%) patients were chronically colonized with *P. aeruginosa*, whereas 26 (40.6%) patients had intermittent infection and had received eradication therapy in each new positive culture for the bacteria according to international guidelines; in 10 (15.6%) patients, *P. aeruginosa* was never isolated from the respiratory secretions and throat swab cultures.

Other bacteria detected at least once in the year before the study were methicillin-sensitive *Staphylococcus aureus* in 55 (91%) patients, methicillin-resistant *S. aureus* in 3 (5%) patients, *Stenotrophomonas maltophilia* in 3 (5%) patients, *Achromobacter xylosoxidans* in 4 (6%) patients, Enterobacteriaceae in 3 (5%) patients, *Burkholderia Gladiolii* in 1/60 patients and *Aspergillus fumigatus* 2/60 patients. The general characteristics of the group of CF patients are shown in Table 1.

### Table 1. General characteristics of patients with cystic fibrosis and their bacteriological status in relation to *P. aeruginosa* infection.

| Characteristics (n = 60) | Chronic *P. aeruginosa* | Intermittent *P. aeruginosa* | *P. aeruginosa* never detected | P     |
|-------------------------|-------------------------|-------------------------------|-------------------------------|-------|
| Age, months (range)     | 58.8 (1–292)            | 22.31 (1–348)                | 62.1 (1–180)                 | 0.086 |
| BMI, kg/m²              | 16.5 ± 3.72             | 15.78 ± 2.46                 | 17 ± 2.23                    | 0.620 |
| Sex (%)                 |                         |                               |                               |       |
| Men                     | 11 (37.9)               | 11 (37.9)                    | 7 (24.1)                     |       |
| Women                   | 13 (41.9)               | 15 (48.4)                    | 3 (9.7)                      |       |

doi:10.1371/journal.pone.0168819.t001
Of the 26 patients with intermittent infection and of the 10 uninfected, 17 (47.2%) patients experienced a new or recent infection with  P. aeruginosa  (within 6 months of obtaining the baseline sample) and received eradication treatment; a second blood sample was obtained in 13 patients to evaluate the performance of sCD40L at the end of eradication treatment. The difference in mean values of sCD40L, before (2893 pg/mL) and after (2073 pg/mL) eradication treatment was statistically significant ($p < 0.045$).

The relationship between cytokines and markers used in each of the groups, and the levels of anti  P. aeruginosa  antibodies and sCD40L had a statistically significant relationship with  P. aeruginosa  infection and chronic colonization as shown in Table 2.

The impact of  P. aeruginosa  infection-colonization on pulmonary deterioration was measured using pulmonary function tests and radiographic and tomographic studies and is shown in Table 3.

The medians of sCD40L for each of the evaluated groups are shown in Fig 1.

The sCD40L performance was optimized using a cutoff of 1255 pg/mL, with an area under the ROC curve of 0.84 (95% CI, 0.71–0.89) (Fig 2).

There was no individual correlation between sCD40L and platelet counts in any of the groups; in contrast, there was a statistically significant moderate negative correlation between AcPa and FEV1 (Pearson = .553; $p = 0.001$), and between AcPa and FVC (Pearson = .537; $p = 0.001$).

Table 2. Comparison of cytokines and biomarkers with chronic/non-chronic/never infected  P. aeruginosa  in patients with cystic fibrosis.

| Cytokines and biomarkers | CPa, n = 24 | NCPa, n = 26 | NI Pa, n = 10 | 95% CI | P |
|--------------------------|------------|-------------|--------------|--------|---|
| TNF-α, pg/mL             | 49.4 ± 15.3| 48.38 ± 9.8 | 59.8 ± 28.8  | CPa 42.9–55.9 | 0.491 |
|                          |            |             |              | NCPa 44.4–52.4 |
|                          |            |             |              | NI Pa 39.2–80.4 |
| IL-6, pg/mL              | 232.1 ± 388.8| 279.3 ± 436.9| 301.7 ± 436.9| CPa 67.9–396.3 | 0.872 |
|                          |            |             |              | NCPa 116.3–442.3 |
|                          |            |             |              | NI Pa 10.78–614.3 |
| ICAM-1, pg/mL            | 1237 ± 82.7 | 1229 ± 196.2 | 1387.1 ± 313.2 | CPa 1202–1271.4 | 0.344 |
|                          |            |             |              | NCPa 1148–1308.3 |
|                          |            |             |              | NI Pa 1208.7–1308.6 |
| VEGF, pg/mL              | 236.5 ± 382.2| 130.8 ± 148.1| 88.6 ± 71.3  | CPa 75.12–397.8 | 0.277 |
|                          |            |             |              | NCPa 71.01–190.62 |
|                          |            |             |              | NI Pa 37.6–139.7 |
| sCD40L, pg/mL            | 1530.9 ± 1162.3| 2243.6 ± 1475.9| 1008.1 ± 746.8| CPa 1040–2021.7 | 0.010 |
|                          |            |             |              | NCPa 1647.4–2839.7 |
|                          |            |             |              | NI Pa 473.9–1542.5 |
| Anti-PaAb (EU)           | 11.60 ± 2.1 | 5.71 ± 2.68 | 3.5 ± 1.8    | CPa 10.7–12.53  | ≤ 0.001 |
|                          |            |             |              | NCPa 4.6–6.8    |
|                          |            |             |              | NI Pa 2.15–4.77 |
| Platelets                | 363.9 ± 120.2| 369.73 ± 95.31| 306.1 ± 79.1 | CPa 313.2–414.7 | 0.243 |
|                          |            |             |              | NCPa 331.2–408.3 |
|                          |            |             |              | NI Pa 329–383.84 |

TNF-α, tumor necrosis factor alpha; IL-6 Interleukin-6; ICAM-1, intracellular adhesion molecule-1; VEGF, vascular endothelial growth factor; sCD40L, soluble CD40 ligand; anti-PaAb, anti-P. aeruginosa antibody; CPa, chronic P. aeruginosa; NCPa, non-chronic P. aeruginosa; NI Pa, never infected P. aeruginosa.

Control values for sCD40L: 160–1000 pg/mL.

doi:10.1371/journal.pone.0168819.t002
Table 3. Comparison of chronic/non-chronic/never infected *P. aeruginosa* infection vs. lung function and imaging studies in patients with cystic fibrosis.

| Lung function | CPA (n = 23) | NCPA (n = 17) | NI PA (n = 6) | 95% CI         | P     |
|---------------|-------------|---------------|--------------|----------------|-------|
| FEV1%, n = 46/60 | 57 ± 26     | 88 ± 16       | 85 ± 19      | CPA 45–68       | ≤0.001|
|               |             |               |              | NCPA 79–96      |       |
|               |             |               |              | NI PA 64–106    |       |
| FVC%, n = 46/60 | 69 ± 21     | 90 ± 15       | 94 ± 9       | CPA 59–79       | ≤0.001|
|               |             |               |              | NCPA 82–98      |       |
|               |             |               |              | NI PA 84–104    |       |
| Bronchiectasis in CT (Balha)* | 4.2 ± 1.9 | 1.72 ± 1.8 | 1.4 ± 1.8 | CPA 3.35–5.1 | ≤0.001|
|               |             |               |              | NCPA 1.7–2.92  |       |
|               |             |               |              | NI PA 0.46–7.3 |       |
| Balha CT score* | 11.2 ± 5.1 | 5.5 ± 4.7    | 3.9 ± 4.1   | CPA 8.9–13.5    | ≤0.001|
|               |             |               |              | NCPA 3.18–7.8  |       |
|               |             |               |              | NI PA 0.46–7.3 |       |
| Brasfield, chest X-ray, n = 60 | 17.9 ± 3.4 | 22.8 ± 2.1  | 23.4 ± 2.2  | CPA 16.5–19.4  | ≤0.001|
|               |             |               |              | NCPA 21.4–23.1 |       |
|               |             |               |              | NI PA 21.9–24.9 |       |

*n = 48/60 FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity, CPA chronic *P. aeruginosa*, NCPA, non-chronic *P. aeruginosa*; NI PA, never infected *P. aeruginosa*.

doi:10.1371/journal.pone.0168819.t003

Fig 1. Medians of sCD40L of the three groups of patients with cystic fibrosis.

doi:10.1371/journal.pone.0168819.g001
Discussion

Lung disease in CF is characterized by progressive destruction of lung tissue due to bacterial infection, inflammation, and airway remodeling [18–19]. Multiple alterations in both innate and acquired immunity in patients with CF have been demonstrated [20–33]. Pathogen-host interactions are important for explaining the severity and persistence of the inflammatory process, with *P. aeruginosa* being the predominant pathogen.

The difficulty in obtaining a representative sample of the lower respiratory airway in infants and young children demonstrates the need for methods that can complement or be an alternative to cultures [34]. An example of ancillary methods is the detection of serum antibodies against *P. aeruginosa*; however, its use in clinical practice remains controversial [35]. In this study, anti-PaAb showed a positive correlation with sCD40L levels, suggesting that its fluctuation reliably reflects the clinical status of infection by this bacterium. In this case, the search for biomarkers of lung damage and the presence of *P. aeruginosa* in the airway of patients with CF is of utmost importance for follow-up and therapeutic management.

In CF patients, platelet activation has been shown to occur and correlates with lung involvement [12, 36]. Ninety-five percent of sCD40L fraction is released by activated platelets [13] and its interaction with the CD40 receptor plays an important role in the induction of efficient humoral and cellular immune responses. The co-stimulatory molecules, including CD40L, are capable of regulating inflammation, and their blood levels as well as their soluble isoforms may serve as markers of activity in diverse pathological conditions, including sepsis [37], tuberculosis [38], and parasitic diseases [39], among others. Patients with CF have an intense systemic
inflammation in which platelets are involved. Platelets can be activated by antigen-antibody complexes, microorganisms and endotoxins, including the lipopolysaccharide of *P. aeruginosa* [40–41]. After activation, they interact with endothelial cells and circulating leukocytes through mediators, contributing significantly to the initiation and spread of diseases and inflammatory processes such as CF lung disease. Given the observed increase in the platelet count of our patients with CF and *P. aeruginosa* infection, we sought to demonstrate the activation of these immune cells in this context by determining sCD40L levels in the blood, finding a correlation between these biomarkers and their concentration and the clinical status of patients with CF.

Normal sCD40L values in healthy controls range from 0.16 ng/mL to 10 ng/mL[42]. Falco et al. [36] showed that patients with CF have increased sCD40L levels in circulating blood compared to healthy controls and that these levels are inversely related to the deterioration of lung function assessed through FEV1, although in this study, all patients, except one, had chronic colonization with *P. aeruginosa*.

The patients in our study were divided into three groups according to the status of infection by *P. aeruginosa*, allowing us to assess the relationship of sCD40L with the presence or absence of the pathogen. The patients with CF showed changes in expression of soluble CD40L; these changes were associated with the presence of *P. aeruginosa* in cultures. sCD40L efficiency was optimized using a cutoff of 1255 pg/mL with an area under the ROC curve of 0.84 (95% CI, 0.71–0.89) for the identification of patients with *P. aeruginosa* infection. In those without chronic *P. aeruginosa* colonization and with a positive culture within six months of the initial sample, eradication treatment was conducted with inhaled tobramycin, and a second sample was obtained at the end of treatment, documenting a statistically significant reduction (*p* < 0.045) in sCD40L levels, suggesting that the severity of infection by *P. aeruginosa* in CF is dynamically reflected by the concentration of sCD40L.

Furthermore, the negative correlation between anti-PaAb and lung function (FEV1 and FVC) shows lung damage as a result of *P. aeruginosa* chronic colonization.

The sCD40L levels were higher in the group of patients with intermittent infection than in those with chronic colonization. First, one likely explanation is that most chronically colonized patients were treated with inhaled tobramycin in ON-OFF cycles, which can reduce inflammation [43] and sCD40L levels. This explanation suggests that serially measuring the serum level of sCD40L in CF patients may be useful in the follow-up of patients and may be helpful in making treatment decisions; the persistence of high levels of sCD40L could reflect a lack of response or resistance to treatment and the need to change or intensify it.

In conclusion, these findings suggest that there is an association between sCD40L levels and *P. aeruginosa* infection in patients with CF. Soluble CD40L appears to reflect infection status with this bacterium, in addition to providing an additional tool for monitoring the evolution of lung deterioration.

**Acknowledgments**

We thank Sergio Lozano-Rodrı́guez, MD, for his critical review of the manuscript.

**Author Contributions**

**Conceptualization:** AEB JCJP LEME PCP GGR.

**Data curation:** AEB JCJP PCP.

**Formal analysis:** CDVV.
Investigation: AEB PCP.
Methodology: AEB JCJP LEME PCP GGR.
Resources: AEB PCP.
Software: CDVV.
Validation: AEB JCJP LEME PCP GGR.
Visualization: AEB JCJP PCP.
Writing – original draft: AEB JCJP PCP.
Writing – review & editing: AEB JCJP LEME PCP GGR CDVV RML.

References
1. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Registry Annual Data Report. 2013 [cited 2016 Mar 12]; Available from: https://www.cff.org/2013_CFF_Patient_Registry_Annual_Data_Report.pdf.
2. Segal E, Renteria F, Fernandez A. Genetica. Fibrosis Quı ´ stica. Buenos Aires: Ediciones Journal; 2004. p. 5–46.
3. Hospital for Sick Children in Toronto. Cystic Fibrosis Mutation Database. 2011 [cited 2016 Mar 18]; http://www.genet.sickkids.on.ca/cftr/app.
4. Cystic Fibrosis Foundation. Clinical and Functional Translation of CFTR (CFTR2). 2016 [cited 2016 Mar 18]; http://www.cftr2.org/.
5. Tirouvanziam R, Khazaal I, Peault B. Primary inflammation in human cystic fibrosis small airways. Am J Physiol Lung Cell Mol Physiol. 2002 Aug; 283(2):L445–51. doi: 10.1152/ajplung.00419.2001 PMID: 12114207
6. Heijerman H. Infection and inflammation in cystic fibrosis: a short review. J Cyst Fibros. 2005 Aug; 4 Suppl 2:3–5.
7. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003 Oct 15; 168(8):918–51. doi: 10.1164/rcrm.200304-505SO PMID: 14554548
8. Koch C. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol. 2002 Sep; 34 (3):232–6. doi: 10.1002/ppul.10135 PMID: 12203855
9. Douglas TA, Brennan S, Gard S, Berry L, Gangell C, Stick SM, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J. 2009 Feb; 33(2):305–11. doi: 10.1183/09031936.0043108 PMID: 19010992
10. Farrell PM, Collins J, Broderick LS, Rock MJ, Li Z, Kosorok MR, et al. Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis. Radiology. 2009 Aug; 252 (2):534–43. doi: 10.1148/radiol.2522081882 PMID: 19703887
11. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992 Mar; 12(3):158–61. PMID: 1641275
12. O’Sullivan BP, Linden MD, Freilinger AL 3rd, Barnard MR, Spencer-Manzon M, Morris JE, et al. Platelet activation in cystic fibrosis. Blood. 2005 Jun 15; 105(12):4635–41. doi: 10.1182/blood-2004-06-2098 PMID: 15705796
13. Blumberg N, Spinelli SL, Francis CW, Taubman MB, Phipps RP. The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol Res. 2009 Dec; 45(2–3):251–60. doi: 10.1007/s12026-009-8106-9 PMID: 19184537
14. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003 Mar; 2(1):29–34. doi: 10.1016/S1569-1993(02)00141-8 PMID: 15463843
15. Brasfield D, Hicks G, Soong S, Tiller RE. The chest roentgenogram in cystic fibrosis: a new scoring system. Pediatrics. 1979 Jan; 63(1):24–9. PMID: 440798
16. Bhatla M, Turcios N, Aponte V, Jenkins M, Leitman BS, McCauley DI, et al. Cystic fibrosis: scoring system with thin-section CT. Radiology. 1991 Jun; 179(3):783–8. doi: 10.1148/radiology.179.3.2027992 PMID: 2027992
17. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005 Aug; 26(2):319–38. doi: 10.1183/09031936.05.00034805 PMID: 16055882
18. Li Z, Kosorok MR, Farrell PM, Laxova A, West SE, Green CG, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA. 2005 Feb 2; 293(5):581–8. doi: 10.1001/jama.293.5.581 PMID: 15687313

19. Pittman JE, Calloway EH, Kiser M, Yeatts J, Davis SD, Drumm ML, et al. Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease. Pediatr Pulmonol. 2011 May; 46(5):497–504. doi: 10.1002/ppul.21397 PMID: 21194167

20. Cohen-Cymberknoh M, Kerem E, Ferkol T, Elizur A. Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications. Thorax. 2013 Dec; 68(12):1157–62. doi: 10.1136/thoraxjnl-2013-203204 PMID: 23704228

21. Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med. 2007; 58:157–70. doi: 10.1146/annurev.med.58.071905.105316 PMID: 17217330

22. Pezzulo AA, Tang XX, Hoeger MJ, Alaiwa MH, Ramachandran S, Moninger TO, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature. 2012 Jul 5; 474(7345):109–13. doi: 10.1038/nature11130 PMID: 22763554

23. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell. 1997 Feb 21; 88(4):553–60. PMID: 9038346

24. Kushwah R, Gagnon S, Sweezey NB. Intrinsic predisposition of naive cystic fibrosis T cells to differentiate towards a Th17 phenotype. Respir Res. 2013; 14:138. doi: 10.1186/1465-9921-14-138 PMID: 24344776

25. Lai E, Teodoro T, Volchuk A. Endoplasmic reticulum stress: signaling the unfolded protein response. Physiology (Bethesda). 2007 Jun; 22:193–201.

26. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol (1985). 1993 Dec; 75(6):2419–24.

27. Lamtothe J, Valvan NV. Burkholderia cenocepacia-induced delay of acidification and phagolysosomal fusion in cystic fibrosis transmembrane conductance regulator (CFTR)-defective macrophages. Microbiology. 2008 Dec; 154(Pt 12):3825–34. doi: 10.1099/mic.0.2008/023200-0 PMID: 19047750

28. Da A, Brown ME, Deriy LV, Li C, Szeto FL, Chen Y, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol. 2006 Sep; 8(8):933–44. doi: 10.1038/ncb1456 PMID: 16921366

29. Brodlie M, Corris PA, Lordan J, Ward C. Interleukin-17 and cystic fibrosis lung disease. Am J Respir Crit Care Med. 2012 Jan 1; 185(1):108–9; author reply 9–10. doi: 10.1164/ajrccm.185.1.108 PMID: 22210793

30. Brodlie M, Lordan J, Ward C. Ceramide and cystic fibrosis lung disease. Am J Respir Crit Care Med. 2011 Jan 1; 183(1):133.

31. Brodlie M, McKean MC, Johnson GE, Gray J, Fisher AJ, Corris PA, et al. Ceramide is increased in the lower airway epithelium of people with advanced cystic fibrosis lung disease. Am J Respir Crit Care Med. 2010 Aug 1; 182(3):369–75. doi: 10.1164/rcrm.200905-079OC PMID: 20395562

32. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, et al. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med. 2004 Feb 5; 350(6):560–9. doi: 10.1056/NEJMoa021218 PMID: 15102009

33. Regamey N, Tsartsali L, Hilliard TN, Fuchs O, Tan HL, Zhu J, et al. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax. 2012 Feb; 67(2):164–70. doi: 10.1136/thoraxjnl-2011-200585 PMID: 22008188

34. Da Silva Filho LV, Tateno AF, Martins KM, Azzuz Chernishev AC, Garcia Dde O, Haug M, et al. The combination of PCR and serology increases the diagnosis of Pseudomonas aeruginosa colonization/infection in cystic fibrosis. Pediatr Pulmonol. 2007 Oct; 42(10):938–44. doi: 10.1002/ppul.20686 PMID: 17720007

35. Mauch RM, Levy CE. Serum antibodies to Pseudomonas aeruginosa in cystic fibrosis as a diagnostic tool: a systematic review. J Cyst Fibros. 2014 Sep; 13(3):499–507. doi: 10.1016/j.jcf.2014.01.005 PMID: 24522086

36. Falco A, Romano M, Iaiichino L, Collura M, Davi G. Increased soluble CD40 ligand levels in cystic fibrosis. J Thromb Haemost. 2004 Apr; 2(4):557–60. doi: 10.1111/j.1538-7836.2004.00683.x PMID: 15102009

37. Lorente L, Martin MM, Varo N, Borreguero-Leon JM, Sole-Violan J, Blanquer J, et al. Association between serum soluble CD40 ligand levels and mortality in patients with severe sepsis. Crit Care. 2011; 15(2):R97. doi: 10.1186/cc10104 PMID: 21406105
38. Hur YG, Kang YA, Jang SH, Hong JY, Kim A, Lee SA, et al. Adjunctive biomarkers for improving diagnosis of tuberculosis and monitoring therapeutic effects. J Infect. 2015 Apr; 70(4):346–55. doi: 10.1016/j.jinf.2014.10.019 PMID: 25452040

39. Subauste CS. CD40 and the immune response to parasitic infections. Semin Immunol. 2009 Oct; 21(5):273–82. doi: 10.1016/j.smim.2009.06.003 PMID: 19616968

40. Coutinho IR, Berk RS, Mannen E. Platelet aggregation by a phospholipase C from Pseudomonas aeruginosa. Thromb Res. 1988 Sep 1; 51(5):495–505. PMID: 3140410

41. Konig B, Jaeger KE, Konig W. Induction of inflammatory mediator release (12-hydroxyeicosatetraenoic acid) from human platelets by Pseudomonas aeruginosa. Int Arch Allergy Immunol. 1994 May; 104(1):33–41. PMID: 7950403

42. Metwalley KA, Farghaly HS, El-Saied AR. Assessment of serum levels of soluble CD40L in Egyptian children and adolescents with type 1 diabetes mellitus: Relationship to microalbuminuria and glycemic control. Indian J Endocrinol Metab. 2013 Nov; 17(6):1024–9. doi: 10.4103/2230-8210.122617 PMID: 24381879

43. Husson MO, Wizla-Derambure N, Turck D, Gosset P, Wallaert B. Effect of intermittent inhaled tobramycin on sputum cytokine profiles in cystic fibrosis. J Antimicrob Chemother. 2005 Jul; 56(1):247–9. doi: 10.1093/jac/dki179 PMID: 15932936